DE3012533A1 - 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-aethyl-7,13,14-trihydroxy-3,5,7,9, 12,14-hexamethyloxacyclopentadecan-2- on und dessen derivate sowie ein verfahren zu deren herstellung - Google Patents
11-aza-4-o-cladinosyl-6-o-desosaminyl-15-aethyl-7,13,14-trihydroxy-3,5,7,9, 12,14-hexamethyloxacyclopentadecan-2- on und dessen derivate sowie ein verfahren zu deren herstellungInfo
- Publication number
- DE3012533A1 DE3012533A1 DE19803012533 DE3012533A DE3012533A1 DE 3012533 A1 DE3012533 A1 DE 3012533A1 DE 19803012533 DE19803012533 DE 19803012533 DE 3012533 A DE3012533 A DE 3012533A DE 3012533 A1 DE3012533 A1 DE 3012533A1
- Authority
- DE
- Germany
- Prior art keywords
- hydrogen
- aza
- acyl
- deoxo
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 10
- -1 alkali metal salts Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 238000006237 Beckmann rearrangement reaction Methods 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004442 acylamino group Chemical group 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 150000008065 acid anhydrides Chemical class 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 229910052987 metal hydride Inorganic materials 0.000 claims description 4
- 150000004681 metal hydrides Chemical class 0.000 claims description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229910000510 noble metal Inorganic materials 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 claims 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 claims 1
- 230000006181 N-acylation Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims 1
- 238000006140 methanolysis reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000002596 lactones Chemical class 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229930006677 Erythromycin A Natural products 0.000 description 5
- 239000002026 chloroform extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100035767 Adrenocortical dysplasia protein homolog Human genes 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186245 Corynebacterium xerosis Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000929940 Homo sapiens Adrenocortical dysplasia protein homolog Proteins 0.000 description 1
- 241000515012 Micrococcus flavus Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241001148137 Salmonella enterica subsp. enterica serovar Panama Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
0,1 | 0,1 | 0,5 | 200 | 200 | 2,5 | 100 |
0,5 | 0,5 | 0,5 | 150 | 200 | 1,0 | 100 |
0,05 | 0,1 | 0,05 | 50 | 175 | 0,5 | 20 |
0,05 | 0,05 | 0,05 | 10 | 10 | 0,1 | 50 |
0,1 | 0,1 | o,5 | 200 | 175 | 2,5 | 50 |
0,05 | 0,1 | 5 | 175 | 200 | 0,5 | 100 |
0,1 | 0,1 | 1,0 | - | - | - | - |
1,0 | 1,0 | 1,0 | - | - | - | - |
50 | 50 | 50 | - | - | - | - |
5,0 | 5,0 | 10 | - | - | - | - |
25 | 25 | 10 | - | - | - | - |
25 | 50 | 10 | - | - | - | - |
50- | 50 | 50 | - | - | - | - |
EO Erythromycin A-oxim
0 | 0,5 | 0,1 | 0,5 | 1,0 |
1/2 | 7,5 | 0,1 | o,5 | 1,0 |
1 | 10 | 0,1 | 0,5 | 1,0 |
2 | 10 | 0,5 | 1,0 | 2,5 |
3 | 10 | 0,5 | 1,0 | 2,5 |
6 | 20 | 0,5 | 1,0 | 2,5 |
M+ 73O
M+ 734-
pK, 6,7 (66 %iges Dimethylformamid-Wasser) IR(CHCl-,) 1725 (C=O Lacton und Ester), 1610 (-CO-N^) und 1235 cm""1 (Acetyl)
N-Propionyl-11-aza~10-deoxo-10-dihydroerythromycin A (V)
Claims (18)
- PmT E W Τ« N WA 1_T E SCHIFF ν. FÜNER STREHL SCHÜBEL-HOPFEBBINGHAUS FINCKMARIAHILFPLATZ 2 & 3, MÖNCHEN 9O POSTADRESSE: POSTFACH 93 O1 6O, D-8OOO MDNCHEN 95PLIVA Pharmazeutische und Chemische FabrikALSO PROFESSIONAL REPRESENTATIVES BEFORS THE EUROPEAN PATENT OPPICgKARL LUOWIQ SCHIFF (19S4 —197S)DIPL. CHEM. OR. ALEXANDER V. FÜNERDIPL. INQ. PETER STREHLDIPL. CHEM. DR. URSULADIPL. INQ. DIETER EaBINOHAUSDR. INQ. DIETER FINCKTELEFON (OSO) 4B3OII4TELEX 8-23 SSS AURO DTELEGRAMME AUROMARCPAT MÜNCHENDEA-2103231. März 198Ο11-AZA-4-O-CLAÜINOSYL-6-O-DESOSAMINYL-15-&THYL-7,13,14-TRIHYDROXY-3,5,7,9,12,14-HEXAMETHYLOXACYCLOPENTADECAN-2-ON UND DESSEN DERIVATE SOWIE EIN VERFAHREN ZU DEREN HERSTELLUNGPatentansprüche1T~Aza-10-deoxo-10-dihydroerybhromycin A und dessen Derivate der allgemeinen FormelCHR1M-K(CH5)20771inspectedworinR1 für Wasserstoff, eine Acyl- oder 4-R-CgH^-SO^Gruppe, worin R eine Alkylgruppe, Halogen oder Acylaniinogruppe darstellt, stehtj undR2' ^3» ß4 1211^- S5' ^e &-ei-ch oder verschieden sein können, für Wasserstoff oder Acylgruppen stehen oder R^ und E5 zusammen eine Carbonylgruppe sind.
- 2. Verbindung nach Anspruch 1, worin R1, R3, R,, R und R1. für Wasserstoff stehen.
- 3. Verbindung nach Anspruch 1, worin R1 und R2 für Acylgruppen und R51 R4 und R^ für Wasserstoff stehen.
- 4. Verbindung nach Anspruch 1, worin R1, R2 und R-, für Acylgruppen und R^ und ß^ für Wasserstoff stehen.
- 5. Verbindung nach Anspruch 1, worin R1, R2, R,, R^ für Acylgruppen stehen und Rr für Wasserstoff steht.
- 6. Verbindung nach Anspruch 1, worin R1 für eine Acylgruppesteht und R0, R-,, R,., Rc für Wasserstoff stehen.
d 3 1V y - 7. Verbindung nach Anspruch 1, worin R1, R3 und R, für Acylgruppen stehen und R. und R^ zusammen eine Carbonylgruppe sind.
- 8. Verbindung nach Anspruch 1, worin R1, R2 und E-, für Wasserstoff stehen und iL· und R^ zusammen eine Carbonylgruppe sind.
- 9. Verbindungen nach Anspruch 1, worin R1 eine 4--R-C6H^-SOp-Gruppe bedeutet, worin R die obige Bedeutung besitzt, und Rp, R,, R^ und R1- für Wasserstoff stehen.
- 10. Verfahren zur Herstellung von 11-Aza-IO-deoxo-IO-dihydroerythromycin A und dessen Derivaten der allgemeinen Formel03 0 0-42/0 771
BADR1NCHworinRx, für Wasserstoff, eine Acyl- oder 4-R-CgH^-S02-Gruppe, worin R eine Alkylgruppe, Halogen oder Acylaminogruppe darstellt,steht, und
Rp, R7, R1 und Rr, die gleich oder verschieden sein können, für Wasserstoff oder Acylgruppen stehen oder R^ und R1-zusammen eine Carbonylgruppe sind^dadurch gekennzeichnet, dass man das durch die Beckmannsche Umlagerung des Erythromycin A-orims erhaltene Produkt e.iner Redulction und anschliessend einer 0- oder N-Acylierung unterwirft. - 11. Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man die Beckmannsche Umlagerung unter Verwendung von 1 bis 2 Mol Sulfochloridznder Formel 4-R-CgH^-SOpCl, worin R Alkyl, Halogen oder Acylamino bedeutet, und 2 bis 4 Mol Alkalimetallsalzen bei 5 C in einem Gemisch von Aceton und Wasser oder einem anderen Lösungsmittel durchführt.
- 12. Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man das gemäss Anspruch 11 erhaltene Produkt katalytisch oder mit komplexen Metallhydriden reduziert, wobei man 11-Aza-10-deoxo-10-dihydroerythromycin A der Formel (1), worin R,,, Rp,
- und R1- Wasserstoff bedeuten, erhält.
- 03 OCH 2/0.7/7.1
- 15. Verfahren nach Anspruch 10 und 12, dadurch gekennzeichnet, dass man die katalytische Reduktion in einem inerten Lösungsmittel, wie z.B. Eisessig, in Gegenwart von Edelmetallen oder deren Oxiden als Katalysatoren "bei Raumtemperatur und einem Druck von 5 bis 70 atm durchführt.14. Verfahren nach Anspruch 10 ·. J, dadurch gekennzeichnet, dass man die Reduktion in absolutem Alkohol, wie z.B. Methanol, mit komplexen Metallhydriden, wie z.B. NaBH^, bei einer Temperatur von etwa 4-0C durchführt.15- Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man dar. geinäao Ansprüchen 11 und 12 erhaltene 11-Aza-IO-deoxQ-10-dehydroerythroraycin A mit Säureanhydriden der Formel RjQd-O-GORjj, worin Rj und Rjj Alkyl bedeuten, umsetzt, wobei man 0,N-ßiacyl-, -Triacyl- oder -Tetraacyl-derivate der Formel (1), worin R,, undR2 Acyl, R7 und R^ Wasserstoff oder Acyl und R1- Wasserstoff bedeuten, erhält.
- 16. Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man mittels Hydrolyse oder Methanolyse der gemäss Anspruch 15 erhaltenen Ο,Ν-Diacylderivabe von 11-Aza-IO-deoxo-IO-dihydroerythromycin A N-Acylderivate der Formel (1), worin R^ Acyl und R2, R-,, R^ und R^ Wasserstoff bedeuten, herstellt.
- 17· Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man das gemäss Ansprüchen 11 und 12 erhaltene 11-Aza-IO-deoxo-10-dihydroerythroiaycin A mit A'thylenkarbonat in Gegenwart von KpCO^ in A'thylacetat oder einem anderen inerten Lösungsmittel umsetzt, wobei man 11-Aza-IO-deoxo—10-dihydroerythromycin A-cyclisches-13,14--karbonat der Formel (1), worin R^,, Rp und R-, Wasserstoff und R^, und R^ eine Carbonylgruppe bedeuten, erhalt.
- 18. Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man das gemäss Anspruch 17 erhaltene 11-Aza-IO-deoxo—10-dihydroerythromycin A-cyclisches 13,14—karbonat mit Säureanhydriden der Formel RjCO-0-CORjj, worin Rj und Rjj Niederalkylreste bedeuten, umsetzt, wobei man Acylderivate der Formel (1), worin R^, Rp und R, Acyl und R1, und R1- eine Carbonylgruppe bedeuten, erhält030042/0771 BAD ORIGINAL19· Verfahren nach Anspruch 10, dadurch gekennzeichnet, dass man das gemäss Ansprüchen 11 und 12 erhaltene 11-Aza-IO-deoxo-IO-dihydroerythroinycin A mit Sulfochloriden der Formel ^--R-G^H^-S worin R Alkyl, Halogen oder Acylamino bedeutet, in Aceton oder in einem anderen Lösungsmittel in Gegenv/art von Alkalien, wir z.B. NapCO,, umsetzt, wobei man Sulfonamide der Formel (1) erhält, worin R^, eine 4-~R-C,-Hy-SOp-Gruppe bedeutet, in welcher R die oben angegebene Bedeutung hat, und R£> R^i JR^ und R^ Wasserstoff bedeuten.030042/0771
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
YU768/79A YU43116B (en) | 1979-04-02 | 1979-04-02 | Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3012533A1 true DE3012533A1 (de) | 1980-10-16 |
DE3012533C2 DE3012533C2 (de) | 1988-09-29 |
Family
ID=25551353
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19803012533 Granted DE3012533A1 (de) | 1979-04-02 | 1980-03-31 | 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-aethyl-7,13,14-trihydroxy-3,5,7,9, 12,14-hexamethyloxacyclopentadecan-2- on und dessen derivate sowie ein verfahren zu deren herstellung |
DE3051049A Expired - Lifetime DE3051049C2 (de) | 1979-04-02 | 1980-03-31 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3051049A Expired - Lifetime DE3051049C2 (de) | 1979-04-02 | 1980-03-31 |
Country Status (10)
Country | Link |
---|---|
US (1) | US4328334A (de) |
JP (1) | JPS57114598A (de) |
AT (1) | AT369750B (de) |
CA (1) | CA1142517A (de) |
CH (1) | CH646440A5 (de) |
DE (2) | DE3012533A1 (de) |
GB (1) | GB2047247B (de) |
SI (1) | SI7910768A8 (de) |
SU (1) | SU1093253A3 (de) |
YU (1) | YU43116B (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5788193A (en) * | 1980-11-21 | 1982-06-01 | Pliva Pharm & Chem Works | 11-aza-10-deoxo-10-dihydroerythromycin a, derivatives and manufacture |
DE3140449A1 (de) * | 1981-03-06 | 1983-10-13 | Sour Pliva farmaceutska, kemijska, prehrambena i kozmetička industrija, 41000 Zagreb | N-methyl-11-aza-10-deoxo-10-dihydro-erythromycine a, verfahren zu ihrer herstellung sowie ihre verwendung |
US4886792A (en) * | 1987-09-03 | 1989-12-12 | Sour Pliva | 10-dihydro-10-deoxo-11-azaerythronolide a compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof |
EP0927722A1 (de) * | 1997-12-31 | 1999-07-07 | PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo | Beta,beta-disubstituierte Derivate von 9-Deoxo-9a-N-ethenyl-9a-aza-9a-homoerythromycin A |
US7414114B2 (en) | 2000-08-23 | 2008-08-19 | Wockhardt Limited | Process for preparation of anhydrous azithromycin |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
ZA835204B (en) * | 1982-07-19 | 1985-02-27 | Pfizer | N-methyl 11-aza-10-deoxo-10-dihydroerythromycin a,intermediates therefor and processes for their preparation |
PH19293A (en) * | 1982-11-15 | 1986-03-04 | Pfizer | Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof |
US4526889A (en) * | 1982-11-15 | 1985-07-02 | Pfizer Inc. | Epimeric azahomoerythromycin A derivative, intermediates and method of use |
JPS59225198A (ja) * | 1983-05-23 | 1984-12-18 | フアイザ−・インコ−ポレ−テツド | 抗菌性を有する9―デオキソ―9a―アザ―9a―ホモエリスロマイシンA,その製造方法および組成物 |
US4492688A (en) * | 1983-11-25 | 1985-01-08 | Pfizer Inc. | Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor |
EP0132026B1 (de) * | 1983-05-23 | 1986-12-30 | Pfizer Inc. | Cyclische Ether, mit antibakterieller Wirkung, von 9-Deoxy-9a-Aza-9a-Homoerythromycin und Zwischenprodukte |
US4464527A (en) * | 1983-06-30 | 1984-08-07 | Pfizer Inc. | Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore |
YU43658B (en) * | 1983-07-18 | 1989-10-31 | Pliva Pharm & Chem Works | Process for preparing 7,16-dioxa-2-aza-10-0-cladinosyl-12,0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo(11.2.1)hexadeca-1(2)-ene-8 |
ATE38519T1 (de) * | 1983-09-06 | 1988-11-15 | Pfizer | Azahomoerythromycin-b-derivate und zwischenprodukte. |
US4465674A (en) * | 1983-09-06 | 1984-08-14 | Pfizer Inc. | Azahomoerythromycin D derivative and intermediates therefor |
US4512982A (en) * | 1984-04-13 | 1985-04-23 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method |
US4518590A (en) * | 1984-04-13 | 1985-05-21 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method |
SI8611592A8 (en) * | 1986-09-12 | 1995-04-30 | Pliva Pharm & Chem Works | Process for preparing complexes of N-methyl-11-aza-10-deoxo-10-dihydroeritromicine A and 11-aza-10-deoxo-10-dihydroeritromicine A with metals |
US5075289A (en) * | 1988-06-07 | 1991-12-24 | Abbott Laboratories | 9-r-azacyclic erythromycin antibiotics |
US5912331A (en) * | 1991-03-15 | 1999-06-15 | Merck & Co., Inc. | Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A |
US5985844A (en) * | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
US5523401A (en) * | 1991-04-09 | 1996-06-04 | Abbott Laboratories | Macrocyclic lactam prokinetic agents |
US5189159A (en) * | 1992-04-02 | 1993-02-23 | Merck & Co., Inc. | 8a-AZA-8a-homoerythromycin cyclic iminoethers |
US5215980A (en) * | 1992-01-17 | 1993-06-01 | Merck & Co., Inc. | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof |
US5210235A (en) * | 1992-08-26 | 1993-05-11 | Merck & Co., Inc. | Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics |
HRP930014A2 (en) * | 1993-01-08 | 1994-08-31 | Pliva Pharm & Chem Works | 9-deoxo-9a-aza-11-deoxy-9a-homoeritromycin a 9a, 11-cyclic carbamates |
US5332807A (en) * | 1993-04-14 | 1994-07-26 | Merck & Co., Inc. | Process of producing 8A- and 9A-azalide antibiotics |
EP0699207B1 (de) * | 1993-05-19 | 1997-06-25 | Pfizer Inc. | Zwischenprodukt für azithromycin |
ES2122905B1 (es) * | 1996-07-11 | 1999-11-16 | Astur Pharma Sa | Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato). |
US6339063B1 (en) * | 1997-09-10 | 2002-01-15 | Merck & Co., Inc. | 9a-azalides as veterinary antimicrobial agents |
NZ502861A (en) * | 1997-09-10 | 2001-03-30 | Merck & Co Inc | Method of treating livestock bacterial respiratory or enteric infections using 9a-azalides |
AP9801420A0 (en) * | 1998-01-02 | 1998-12-31 | Pfizer Prod Inc | Novel macrolides. |
HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
UA70972C2 (uk) | 1998-11-20 | 2004-11-15 | Пфайзер Продактс Інк. | 13-членні азаліди і їх застосування як антибіотиків |
HRP990116B1 (en) * | 1999-04-20 | 2007-10-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | NOVEL 8a AND 9a- 15-MEMBERED LACTAMES |
HRP990130B1 (en) * | 1999-05-03 | 2004-06-30 | Pliva D D | HALOGEN DERIVATIVES 9a-N-(N'-ARYLCARBAMOYL)- AND 9a-N-(N'-ARYLTHIOCARBAMOYL)-9-DEOXO-9a-AZA-9a OF HOMOERYTHROMYCIN A |
PL352720A1 (en) * | 1999-05-24 | 2003-09-08 | Pfizer Products Inc. | 13-methyl-erythromycin derivatives |
US6764996B1 (en) * | 1999-08-24 | 2004-07-20 | Abbott Laboratories | 9a-azalides with antibacterial activity |
EP1101769A3 (de) * | 1999-11-18 | 2001-10-24 | Pfizer Products Inc. | Stickstoff-enthaltend Erythromycin-Derivate |
ES2260047T3 (es) | 2000-07-25 | 2006-11-01 | Laboratorio Silanes, S.A. De C.V. | Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a. |
ES2179756B1 (es) * | 2000-11-30 | 2004-10-01 | Ercros Industrial, S.A. | Procedimiento de obtencion de azaeritromicina. |
KR100491183B1 (ko) * | 2001-03-21 | 2005-05-25 | 한미약품 주식회사 | 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물 |
HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
IL158059A0 (en) | 2001-04-27 | 2004-03-28 | Pfizer Prod Inc | Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives |
BR0209918A (pt) | 2001-05-22 | 2004-03-30 | Pfizer Prod Inc | Formas cristalinas da azitromicina |
US6861413B2 (en) * | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
CZ2004232A3 (cs) * | 2001-08-21 | 2005-10-12 | Pfizer Products Inc. | Jednorázová dávka azithromycinu |
WO2003070173A2 (en) * | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
CA2476423A1 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
EP1482957A4 (de) * | 2002-02-15 | 2006-07-19 | Merckle Gmbh | Antibiotische konjugate |
US20040186063A1 (en) * | 2002-02-15 | 2004-09-23 | Hans-Jurgen Gutke | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
ITMI20021209A1 (it) * | 2002-06-04 | 2003-12-04 | Chemi Spa | Processo di preparazione di azitromicina ad elevata purezza |
HRP20020779A2 (en) * | 2002-09-27 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | NEW 3-DECLADINOSYL DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICIN A 9a, 11-CYCLIC CARBAMATES |
ITMI20022292A1 (it) * | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
HRP20020885B1 (en) * | 2002-11-11 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A |
HRP20020991A2 (en) * | 2002-12-12 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | N"-Substituted 9a-N-(N'-carbamoyl-Gamma-aminopropyl), 9a-N-(N'? -thiocarbamoyl-Gamma-aminopropyl), 9a-N-(N'-((Beta-cyanoethyl)-N'-carbamoyl-Gamma? -aminopropyl) and 9a-N-(N'-(Beta-cyanoethyl)-N'-thiocarbamoyl-Gamma? -aminopropyl) derivatives of 9-de |
HRP20030381B1 (en) * | 2003-05-14 | 2007-05-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A |
JPWO2005019238A1 (ja) * | 2003-08-22 | 2006-10-19 | 明治製菓株式会社 | 新規アザライド及びアザラクタム誘導体とその製造法 |
US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
CN101228171A (zh) * | 2005-07-26 | 2008-07-23 | 默克勒有限公司 | 作为5-脂氧化酶和环加氧酶抑制剂的吡咯里嗪和中氮茚化合物的大环内酯偶联物 |
CN102260306B (zh) * | 2011-07-22 | 2012-07-18 | 山东鲁抗舍里乐药业有限公司 | 一种制备泰拉霉素的方法 |
CN102863486A (zh) * | 2012-09-18 | 2013-01-09 | 太仓市运通化工厂 | 一种9-脱氧-9a-氮杂-9a-高红霉素的合成方法 |
EA037729B1 (ru) | 2017-02-22 | 2021-05-14 | АйЭсАр ИММЬЮН СИСТЕМ РЕГЬЮЛЕЙШН ХОЛДИНГ АБ (ПАБЛ) | Новый иммуностимулирующий макролид |
AU2018225389B2 (en) | 2017-02-22 | 2021-09-02 | ISR Immune System Regulation Holding AB (publ) | Novel immune stimulating compound |
CA3190926A1 (en) | 2020-09-03 | 2022-03-10 | Ola Winqvist | Vaccine comprising an antigen and a tlr2 agonist |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU31319B (en) * | 1967-08-03 | 1973-04-30 | Pliva Pharm & Chem Works | Postupak za dobijanje acil derivata eritromicin oksima |
GB1100504A (en) * | 1967-08-16 | 1968-01-24 | Pliva Pharm & Chem Works | Erythromycin oxime and 9-amino-3-o-cladinosyl-5-o-desosaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecane-13-olide |
US3652537A (en) * | 1969-11-21 | 1972-03-28 | Lilly Co Eli | Epierythromycylamine and epierythromycyl b amine |
-
1979
- 1979-04-02 SI SI7910768A patent/SI7910768A8/sl unknown
- 1979-04-02 YU YU768/79A patent/YU43116B/xx unknown
-
1980
- 1980-03-28 US US06/134,816 patent/US4328334A/en not_active Expired - Lifetime
- 1980-03-31 DE DE19803012533 patent/DE3012533A1/de active Granted
- 1980-03-31 GB GB8010833A patent/GB2047247B/en not_active Expired
- 1980-03-31 DE DE3051049A patent/DE3051049C2/de not_active Expired - Lifetime
- 1980-04-01 CH CH257280A patent/CH646440A5/de not_active IP Right Cessation
- 1980-04-01 CA CA000348934A patent/CA1142517A/en not_active Expired
- 1980-04-02 SU SU802903453A patent/SU1093253A3/ru active
- 1980-04-02 AT AT0179380A patent/AT369750B/de not_active IP Right Cessation
- 1980-04-02 JP JP55042067A patent/JPS57114598A/ja active Granted
Non-Patent Citations (1)
Title |
---|
NICHTS ERMITTELT * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5788193A (en) * | 1980-11-21 | 1982-06-01 | Pliva Pharm & Chem Works | 11-aza-10-deoxo-10-dihydroerythromycin a, derivatives and manufacture |
DE3140449A1 (de) * | 1981-03-06 | 1983-10-13 | Sour Pliva farmaceutska, kemijska, prehrambena i kozmetička industrija, 41000 Zagreb | N-methyl-11-aza-10-deoxo-10-dihydro-erythromycine a, verfahren zu ihrer herstellung sowie ihre verwendung |
US4886792A (en) * | 1987-09-03 | 1989-12-12 | Sour Pliva | 10-dihydro-10-deoxo-11-azaerythronolide a compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof |
EP0927722A1 (de) * | 1997-12-31 | 1999-07-07 | PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo | Beta,beta-disubstituierte Derivate von 9-Deoxo-9a-N-ethenyl-9a-aza-9a-homoerythromycin A |
US7414114B2 (en) | 2000-08-23 | 2008-08-19 | Wockhardt Limited | Process for preparation of anhydrous azithromycin |
Also Published As
Publication number | Publication date |
---|---|
DE3051049C2 (de) | 1991-08-22 |
ATA179380A (de) | 1982-06-15 |
JPS6364438B2 (de) | 1988-12-12 |
CA1142517A (en) | 1983-03-08 |
JPS57114598A (en) | 1982-07-16 |
SU1093253A3 (ru) | 1984-05-15 |
GB2047247A (en) | 1980-11-26 |
YU43116B (en) | 1989-04-30 |
CH646440A5 (de) | 1984-11-30 |
DE3012533C2 (de) | 1988-09-29 |
SI7910768A8 (en) | 1996-06-30 |
YU76879A (en) | 1982-10-31 |
GB2047247B (en) | 1983-05-25 |
US4328334A (en) | 1982-05-04 |
AT369750B (de) | 1983-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3012533A1 (de) | 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-aethyl-7,13,14-trihydroxy-3,5,7,9, 12,14-hexamethyloxacyclopentadecan-2- on und dessen derivate sowie ein verfahren zu deren herstellung | |
DE3140449C2 (de) | N-Methyl-11-aza-10-deoxo-10-dihydro-erythromycine A, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
DE68922241T2 (de) | Verfahren zur Herstellung von Erythromcin A-oxim oder eines Salzes davon. | |
DE69909455T2 (de) | Polyethoxylierte ascorbinsäurederivate als neue antioxidantien und verfahren zu ihrer herstellung | |
DD211565A5 (de) | Verfahren zur herstellung von 4"-epi-erythromycin a und derivaten hiervon als brauchbare antibakterielle mittel | |
DE2740950C2 (de) | ||
DE2322655C2 (de) | Prostaglandin F↓2↓↓α↓-ester, Verfahren zu deren Herstellung und deren Verwendung zur Reinigung von Prostaglandin-F↓2↓↓α↓ | |
DE2655731B2 (de) | Verfahren zur Herstellung von 3', 4'-Didesoxykanamycin B | |
DE1925230C3 (de) | Verfahren zur Herstellung des Antibiotikums Streptozotocin | |
DE2929058A1 (de) | Anorganische salze von trimethylammoniumderivaten der polyenmakrolide, insbesondere anorganische salze von methylestern dieser derivate, und verfahren zu deren herstellung | |
DE2622638C2 (de) | Rifamycin-Verbindungen | |
DE2409675C3 (de) | 5-Hydroxytryptophan-Derivate und Verfahren zu ihrer Herstellung | |
DE2258239A1 (de) | Zimtsaeure- und dihydrozimtsaeurederivate und verfahren zu ihrer herstellung | |
DE2057188C3 (de) | Erythromycyl-B-amin und Verfahren zu dessen Herstellung | |
DE1076676B (de) | Verfahren zur Herstellung von 6-Desocytetracyclinen | |
DE977143C (de) | Verfahren zur Herstellung wasserloeslicher Derivate des Rutins | |
DE875804C (de) | Verfahren zur Herstellung von Umwandlungsprodukten des Pentaerythrit-dichlorhydrin-monoschwefligsaeureesters | |
DE2425663A1 (de) | Cyclodextrinderivate sowie verfahren zu ihrer herstellung | |
DE1935358C (de) | Verfahren zur Herstellung von O Acyldecarbamyl mitomycin C den vaten | |
DE1470196C (de) | 1 Hydroxymethyl colchicindenvate und Verfahren zu ihrer Herstellung | |
CH639082A5 (de) | Bicyclische lactol-methyl-aether und ein verfahren zu ihrer herstellung. | |
DE2653398A1 (de) | Verfahren zur herstellung von 5-fluor-uracil-derivaten | |
DE1918316B2 (de) | Mitomycinderivate und verfahren zu ihrer herstellung | |
DE1943901A1 (de) | Cardenolid-3-[2',3'-didesoxyglykoside] und Verfahren zu ihrer Herstellung | |
CH467799A (de) | Verfahren zur Herstellung von Antibiotika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8128 | New person/name/address of the agent |
Representative=s name: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS |
|
8110 | Request for examination paragraph 44 | ||
8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3051049 Format of ref document f/p: P |
|
Q171 | Divided out to: |
Ref country code: DE Ref document number: 3051049 |
|
AH | Division in |
Ref country code: DE Ref document number: 3051049 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
AH | Division in |
Ref country code: DE Ref document number: 3051049 Format of ref document f/p: P |